Navigation Links
NanoVibronix Receives Wound Healing Indications in Europe for its PainShield(TM) Device
Date:4/21/2009

NESHER, Israel, April 21 /PRNewswire/ -- NanoVibronix, a medical device company specializing in applications that implement surface ultrasound waves, announced that its novel device has received CE approval in Europe for additional claims of wound healing. PainShield is the first hands-free, patch-based device that uses surface ultrasound waves for therapeutic treatment of wounds. The innovative PainShield consists of a disposable patch connected to a portable driver. PainShield for wound therapy will be introduced at the upcoming European Wound Management Association (EWMA) conference in Helsinki, Finland on May 20 - 22, 2009.

"My experience with PainShield has shown that it is one of the most striking therapeutic modalities in chronic wound care. PainShield implements the benefits of ultrasound to enhance the therapeutic processes required for chronic wound healing, and has shown to do that repeatedly both in the clinical and home setting. ", stated Dr. Jonathan Rosenblum, Director, Diabetic Foot Service, Shaare Zedek Medical Center, Jerusalem, Israel. Dr. Rosenblum will be presenting his experience with PainShield for chronic wounds at the International Conference of Dermatology (ICD), Prague, Czech Republic on May 20 - 24, 2009.

Dr. Leon Gilad, Chief of Wound Care at Hadassah University Medical Center, Jerusalem, Israel, said, "The beneficial properties of low frequency, low intensity ultrasound in a compact, convenient patch allows for a whole new dimension in wound therapy. The ability to place the PainShield patch on healthy skin adjacent to the wound allows the ongoing wound care to continue uninterrupted, while therapeutic ultrasound is provided simultaneously to the wound site. In addition to the wound healing benefits of the PainShield, we have seen a dramatic diminishing of wound pain when pain was present."

NanoVibronix CEO, Dr. Harold Jacob, added, "PainShield, which implements our unique low frequency ultrasound platform, has been shown in a number of independent studies to have powerful tissue regenerative properties. NanoVibronix has created a platform that allows physicians to easily apply therapeutic ultrasound to assist in wound healing without interfering with any of the other modalities that are being utilized. Our simple-to-use, portable patch-based device can treat wounds in the hospital or at home, allowing patients to continue with their daily activities."

About the Company

NanoVibronix, located in Nesher Israel, develops medical devices that implement its proprietary therapeutic ultrasound technology. The innovative portable PainShield device for treatment of pain gained FDA clearance in October 2008. The Company is planning to launch the product in the USA during the second half of 2009. The company has also developed a unique line of catheter-based disposable ultrasound devices designed to treat catheter associated injury including pain, discomfort and biofilm formation. The first two products in this family are the UroShield(TM) for indwelling urinary catheters and the NG-Shield(TM) for indwelling Nasogastric tubes.

   http://www.nanovibronix.com

    For more information, please contact:

    Amir Rippel, VP Marketing
    NanoVibronix Ltd.
    Tel: +972-4-820-0581
    Fax: +972-4-820-2794
    info@nanovibronix.com



'/>"/>
SOURCE NanoVibronix Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market is ... Low drug registration cost in Latin American countries and continuous ...
(Date:4/19/2017)... YORK , April 19, 2017 Cardiology devices ... the projected period The Cardiology Devices segment is ... than US$ 15 Mn in 2018 over 2017. By the ... a market valuation close to US$ 700 Mn, expanding at ... Devices segment dominated the Asia Pacific ...
(Date:4/19/2017)... MOUNTAIN VIEW, Calif. , April 19, 2017 /PRNewswire/ ... that it will release financial results for the first ... May 3, 2017.  The Company,s management team will host ... / 5:30 p.m. ET. Investors interested in ... dialing (844) 707-0665 for domestic callers or (703) 326-3030 ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may be ... conditions and has helped many women become pregnant upon treating their diagnosis. ... and simple outpatient evaluations. We can provide the necessary information to diagnose ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... domain expertise for sponsors and CROs to speed clinical development, has released ... software platform. Bioclinica AGILE RTSM provides seamless clinical supply forecasting ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... committed to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne ... (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced today. , ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now ... Invisalign® in Lutz, FL. With the help of this highly-effective, yet convenient ... fewer potential complications, more discretion and less pain. , Drs. Sarah Jockin, Nicole ...
(Date:4/25/2017)... ... ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace – from medical ... heartened by the industry’s current surge. But another thing that unifies them is a ... last they can simply, safely and effectively end their aroma anguish thanks to a ...
Breaking Medicine News(10 mins):